Moderna, Inc.’s stock price surges to $26.93, marking a robust 3.38% increase – a promising investment opportunity

Moderna, Inc. (MRNA)

26.93 USD +0.88 (+3.38%) Volume: 10.09M

Moderna, Inc.’s stock price sees a promising rise, trading at 26.93 USD with a 3.38% increase this session, supported by a strong trading volume of 10.09M. Yet, the stock faces a year-to-date setback, down by 35.23%. Stay updated on MRNA’s market performance.

Latest developments on Moderna, Inc.

Today, Moderna faces a fluctuation in its stock price as the U.S. Health and Human Services (HHS) abruptly cancels a contract worth over $700 million for the development of a bird flu vaccine. This decision comes amidst uncertainties surrounding the vaccine and the company’s funding for late-phase trials. The Trump administration’s revocation of the contract, despite promising test results reported by Moderna, raises concerns about the future of the company’s vaccine projects. The termination of the contract highlights the challenges Moderna is currently facing in the development of vaccines for flu pandemics, including the H5 avian flu. This unexpected development may impact Moderna’s financial standing and strategic diversification plans moving forward.

Moderna, Inc. on Smartkarma

Analyst coverage on Moderna by Baptista Research on Smartkarma highlights the company’s recent earnings and strategic outlook. The first-quarter 2025 revenues for Moderna stood at $0.1 billion, with a net loss of $1 billion, in line with company expectations. Despite the loss, reflecting the seasonal nature of its respiratory vaccine business, the company is optimistic about its oncology innovations and pipeline expansion post-Covid vaccine.

Furthermore, Baptista Research‘s analysis of Moderna’s financial results for 2024 reveals both opportunities and challenges. The company reported a total revenue of $3.2 billion, a 53% decrease from the previous year, with a net loss of $3.6 billion. This analysis suggests that Moderna’s mRNA platform may fuel a multi-billion-dollar pipeline beyond the challenges posed by Covid-19, positioning the company for future growth and innovation.

A look at Moderna, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc. operates as a biotechnology company that focuses on the discovery and development of messenger RNA therapeutics and vaccines. The company has received positive scores in Value, Resilience, and Momentum, indicating a promising long-term outlook. With a strong emphasis on developing mRNA medicines for various diseases, Moderna’s high scores in these key factors suggest that it is well-positioned for growth and success in the future.

Although Moderna scored lower in Dividend and Growth, its overall outlook remains positive due to its strengths in other areas. The company’s emphasis on innovative technologies and its ability to adapt to market changes have contributed to its favorable scores. Investors may find Moderna to be a promising investment opportunity based on its Smartkarma Smart Scores and its focus on developing cutting-edge therapies for a range of medical conditions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma